Clinical Development of Oncology Products in Japan – the 2nd Largest Market for Innovation

Register free: http://www.appliedclinicaltrialsonline.com/act_w/clinical_development

​Event Overview:
Japan is the second largest market for branded pharmaceuticals and innovation and continues to show strong year-on-year growth. Continuous investment in development in Japan is creating many opportunities and growing the potential for multinational biopharma companies.

This is driven in part by Oncology. With recent advances in genomic analysis technology, such as next generation sequencing (NGS), progress is being made in establishing genomic cancer medicine, whereby effective therapies are selected based on the results of genomic analysis of each individual patient.

In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovative product development. Such measures include accelerated review systems such as Sakigake and Conditional Early Approval. Other driving factors are related to shifts in population demographics leading to over 1 million cancer incidence in Japan each year.

Join IQVIA Japan as we discuss opportunities within the Japanese Oncology market and how you can take advantage to increase the value of your Oncology assets.

3 Key take-aways:

• To obtain the information about the Oncology market in Japan
• How to seize the opportunity in this strong potential market.
• Overview and changes in the Japanese Regulatory Environment and international development strategy

Speaker: Alan Thomas, Director, Thought Leadership, IQVIA Japan Group

Time and Date: Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST

On demand available after final airing until Nov. 19, 2021

Register free: http://www.appliedclinicaltrialsonline.com/act_w/clinical_development